🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Adial Pharmaceuticals, Inc. ADIL PHARMA

Healthcare · Biotechnology · United States
https://www.adial.com
Company Profile ↓
$6.65
-33.50% 1Y
Mkt Cap$19.51M
P/E-0.38
P/B-0.41
52W High$10.50
52W Low$1.36
Book Value$-14.62
EPS (TTM)$-17.71

Company Overview

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

Growth & Price Performance

Stock Price Performance

1 Year:-33.50%
6 Months:+286.63%
3 Months:+200.90%
1 Month:+67.09%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 58% of range
$1.36 $10.50
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross5d ago
  • RSI (14)66.93 · Neutral
Price Performance
1M+67.09%
3M+200.90%
6M+286.63%
1Y-33.50%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 36.7% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.38
Industry PE
24.83
Forward P/E
-0.89
PEG Ratio
-
Book Value
$-14.62
Price to Book
-0.41
P/S
-
EV/EBITDA
-2.37
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-147.82%
ROE
-
ROA
-40.02%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-1.48
EPS (TTM)
$-17.71

Balance Sheet & Liquidity

Debt/Equity
3.93
Quick Ratio
5.61
Current Ratio
5.63
Debt
$0
Total Assets
$5.23M
Current Assets
$4.80M
Working Capital
$4.78M

Ownership

Promoter Holding
7.08%
Chg in Prom Hold
2.83%
FII / Inst Holding
29.85%
Chg in FII Hold
-0.45%

Financial Snapshot

Enterprise Value
$19.51M
Total Revenue (TTM)
$0
EBITDA
$-11.49M
Free Cash Flow
$-3.93M
Operating Cash Flow
$-11.13M
Shares Outstanding
2.93M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ADIL Adial Pharmaceuticals, Inc. PHARMA 6.65 -0.38 $19.51M 0.00% -147.82% - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ------------------------00000
Cost of Revenue -----------------------------
Gross Profit -----------------------------
Operating Expenses ------------------------2.27M1.88M1.76M1.89M2.00M
Operating Income -241.49K-262.42K-339.51K-1.74M-3.82M-2.25M-2.16M-1.75M-2.30M-1.82M-3.34M-4.84M-4.40M-4.06M-3.06M-3.24M-2.55M-2.92M-1.48M-1.36M-1.85M-2.29M-2.21M--2.27M-1.88M-1.76M-1.89M-2.00M
EBITDA -------------------------2.27M-1.88M-1.76M-1.89M-2.00M
Interest Expense -----------------------------
Pretax Income -------------------------2.23M-1.96M-1.79M-2.00M-2.02M
Tax Provision -----------------------0-----
Net Income -264.27K-292.63K-378.95K-1.79M-8.19M-2.68M-2.13M-1.72M-2.28M-1.81M-3.34M-4.83M-4.44M-4.32M-2.91M-3.85M-3.11M-2.91M1.09M-1.38M-6.48M-2.46M-2.19M--2.23M-1.96M-1.79M-2.00M-2.02M
Diluted EPS -------------0.25-0.22-0.13-3.96-3.02-0.110.96-1.18-2.19-0.59-0.38--8.52-4.50-2.00--1.48
R&D Expense 57.86K27.80K55.51K76.89K188.44K686.91K1.21M864.28K1.06M888.01K1.85M2.05M2.32M1.69M596.34K679.97K696.07K676.43K429.90K207.13K454.28K1.01M1.03M-746.89K732.32K521.07K-432.53K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -----0000
Cost of Revenue ---------
Gross Profit ---------
Operating Expenses -----10.86M6.89M8.28M7.80M
Operating Income -995.29K-6.99M-8.24M-10.93M--10.86M-6.89M-8.28M-7.80M
EBITDA ------10.86M-6.89M-8.28M-7.80M
Interest Expense ---------
Pretax Income ------10.80M-7.00M-13.20M-7.98M
Tax Provision -----94.08K000-
Net Income -1.14M-11.63M-8.59M-10.89M--12.73M-5.12M-13.20M-7.98M
Diluted EPS ------317.75-90.00-68.01-11.93
R&D Expense 182.11K368.46K3.97M5.85M8.40M1.95M1.27M3.23M2.62M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -34.55K4.70M7.68M5.49M-5.73M4.74M5.04M6.67M
Current Assets ------4.78M3.20M4.06M6.18M
Cash & Equivalents 87.99K18.25K3.87M6.78M4.40M-4.00M2.83M3.75M5.88M
Inventory ----------
Receivables ----------
Total Liabilities ----1.51M-2.46M653.08K975.86K1.40M
Current Liabilities -1.03M257.97K539.05K1.51M-1.79M653.08K975.86K1.40M
Long Term Debt ----------
Total Debt -----256.96K207.38K---
Total Equity -103.49K-997.55K4.44M7.14M3.99M-3.28M4.08M4.07M5.28M
Shares Outstanding ------42.70K66.54K258.98K1.11M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -494.86K-2.50M-6.34M-7.63M--11.19M-6.81M-6.92M-6.49M
Investing Cash Flow 35.12K---350.00K-01.50M0150.00K
Financing Cash Flow 390.00K6.35M9.25M5.61M-9.13M4.13M7.85M8.47M
Capital Expenditure -----64.61K----
Free Cash Flow ------11.19M-6.81M-6.92M-6.49M
Net Change in Cash ------2.06M-1.17M923.44K2.13M
Share Buybacks ------1.66K--

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------
Operating Margin % ---------
Net Margin % ---------
ROE % 114.2%-261.9%-120.3%-273.3%--388.6%-125.5%-324.4%-151.2%
ROCE % 99.8%-157.3%-115.5%-274.2%--275.5%-168.7%-203.6%-147.8%

Shareholding Pattern

Insiders
7.08%
Institutions
29.85%
Public Float
32.13%

Top Institutional Holders

#Holder% HeldSharesValue
1 Jane Street Group, LLC 1.22% 32.12K $156.10K
2 Citadel Advisors Llc 1.13% 29.55K $143.60K
3 Stonex Group Inc. 0.75% 19.70K $95.74K
4 UBS Group AG 0.73% 19.15K $93.05K
5 Geode Capital Management, LLC 0.47% 12.39K $60.23K
6 China Universal Asset Management Co., Ltd. 0.30% 8.00K $38.88K
7 Vanguard Fiduciary Trust Co 0.22% 5.88K $28.57K
8 Vanguard Capital Management LLC 0.22% 5.83K $28.34K
9 Manchester Capital Management, LLC 0.07% 1.92K $9.35K
10 Tower Research Capital LLC (TRC) 0.05% 1.42K $6.90K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ADIL

Yahoo Finance ue, 25 Aug 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 s…

Yahoo Finance ue, 16 Jun 2026

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew Davidson and Julie Sai…

Yahoo Finance hu, 11 Jun 2026

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

Yahoo Finance hu, 11 Jun 2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora’s oral candidate, AT177, …

Yahoo Finance Mon, 11 May 2026

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictio…

Yahoo Finance Wed, 29 Apr 2026

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approachGLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial…

ADIL — Frequently Asked Questions

What is the current share price of Adial Pharmaceuticals, Inc. (ADIL)?

As of 2026-09-19 21:16 PDT, Adial Pharmaceuticals, Inc. (ADIL) trades at $6.65 on NasdaqCM. Its 52-week range is $1.36 to $10.50.

What is the market capitalisation of ADIL?

Adial Pharmaceuticals, Inc. (ADIL) has a market capitalisation of $19.51M on NasdaqCM.

What is the P/E ratio of ADIL?

ADIL trades at a trailing price-to-earnings (P/E) ratio of -0.38. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.41.

Is ADIL a good stock to buy?

This page provides a data-driven analysis of Adial Pharmaceuticals, Inc. (ADIL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space